about
Molecular markers of early Parkinson's disease based on gene expression in bloodParkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1Dopamine covalently modifies and functionally inactivates parkinModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreParkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder.Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effectsSerum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathyA First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal FluidParkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structuresα-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system.Respiratory infection of mice with mammalian reoviruses causes systemic infection with age and strain dependent pneumonia and encephalitis.GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains.Multiple system atrophy: a primary oligodendrogliopathy.Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.Vertebral artery dissection with a normal-appearing lumen at multisection CT angiography: the importance of identifying wall hematoma.Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition.RING finger 1 mutations in Parkin produce altered localization of the protein.beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms.K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.Hashimoto's encephalopathy mimicking Creutzfeldt-Jakob disease: brain biopsy findings.Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain.Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies.Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin.Detection of soluble forms of the beta-amyloid precursor protein in human plasma.Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo.
P50
Q24292810-C85E9C0D-3F1F-4847-B8AD-B89A7E84C449Q24308897-2B9472CD-805D-462D-A996-F631D08AD428Q24338423-667BF760-11BE-494E-8781-EA45275B4F71Q29048624-B7C5DCC2-D868-4BB8-ABE5-D23826FFF8C4Q33344464-10B61421-657F-42D9-AD0B-45FE918CD8DBQ33734084-B13EB7B7-E30E-4552-A798-DC66F82A1078Q34648414-AAAAA213-6F48-4BA7-B6BF-0AC4CCB69786Q35122963-89E722F8-8054-4386-8469-08CEED1D093EQ35999591-0C26D8C8-185F-4FDB-9C22-96E2D1054289Q36037105-E88E10C8-565B-44E7-87E6-1D0FAD96A698Q36044595-D5C8F28F-9283-477A-A85B-A651545B6959Q36707616-70A4B5B5-D0B4-49FC-B764-D57D405F3455Q36825286-F89061E2-DEAD-430B-94B8-AC912F364D4DQ37102231-DF65946D-EB7E-4608-B5A8-F631A4DE734EQ37125332-576E2A28-9BD6-4427-89D0-3AC5AC779C6FQ37282526-173B78BD-42EC-4F52-A849-BD6BDC8B202FQ37295073-99CE861F-E1A2-4792-83F1-0CAC04F88EB2Q37375625-B732A6F9-D306-40FA-9EED-040D55EF95DBQ37463473-4ED99CE7-FE15-40FC-A6C3-0047BB13F501Q37800101-030BD04D-47D6-4200-AC18-9CE576603B99Q37983366-FF424DAB-DE81-41F7-BE0E-4CEEDC57FCAFQ38006645-ECD100BB-8112-4998-B1FE-DF4A9ADBA02FQ38486351-541FC391-E67E-4B66-918A-16CBFA56CF04Q38603309-E60B91DF-6356-4B45-83FB-9DE993388638Q39562553-24663679-8620-49B2-82C1-7E3A37D6532BQ39783457-31F93A48-CDCB-48F9-9A4F-75BA775E4FB1Q40071251-4535AB7F-C3E1-4025-A386-AF26D372E810Q40422333-BF2BBF9A-2B23-443C-B2A2-4A372D8DBD31Q40629977-AA5B8596-8BC8-405D-9C37-4318CD30ACF8Q41573328-513F2A44-D7E0-442D-8EAD-37B2EAB28E08Q41636978-2E814847-7C7A-4441-B1F4-782D6DD5562AQ43069805-3BCC4399-BA7A-4C3B-88D1-78F989726D7DQ47402281-8967875B-2E35-40AB-BECF-DF4B3D32BBE8Q48157844-59CE57C6-B1C9-4889-AAE2-9953CD0F2156Q48176610-DD66BCD3-2651-4EDF-9EFB-F6E2FA5B6E51Q48438362-39C20D93-47C9-4BA8-A14A-6ABBB986A867Q48883999-7851608C-4369-41FC-8CCF-57EC09A71C91Q49050468-3269118A-0521-4D53-AA5F-214C98BC4B19Q51787088-818EAD55-53AB-434F-B128-E5016D11B43CQ52678048-72F2A02E-CE85-4C5F-9025-71E44005730C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael G Schlossmacher
@ast
Michael G Schlossmacher
@en
Michael G Schlossmacher
@es
Michael G Schlossmacher
@nl
Michael G Schlossmacher
@sl
type
label
Michael G Schlossmacher
@ast
Michael G Schlossmacher
@en
Michael G Schlossmacher
@es
Michael G Schlossmacher
@nl
Michael G Schlossmacher
@sl
altLabel
Michael G. Schlossmacher
@en
Michael Schlossmacher
@en
prefLabel
Michael G Schlossmacher
@ast
Michael G Schlossmacher
@en
Michael G Schlossmacher
@es
Michael G Schlossmacher
@nl
Michael G Schlossmacher
@sl
P106
P21
P31
P4012
P496
0000-0002-0394-0300